,Interacting Gene/Enzyme,Allele name,Genotype(s),Defining Change(s),Type(s),Description,Details
0,"HLA class II histocompatibility antigen, DQ alpha 1 chain",HLA-DQA1*02:01,Not Available,HLA-DQA1*02,ADR Directly Studied,The presence of this polymorphism in TNXB may indicate an increased risk of drug-induced ALT-elevations leading to hepatotoxicity when treated with lapatinib.,Details
1,"HLA class II histocompatibility antigen, DRB1-11 beta chain",HLA-DRB1*07:01,Not Available,HLA-DRB1*07,ADR Directly Studied,The presence of this polymorphism in TNXB may indicate an increased risk of drug-induced ALT-elevations leading to hepatotoxicity when treated with lapatinib.,Details
2,"HLA class II histocompatibility antigen, DQ beta 1 chain",HLA-DQB1*02:02,Not Available,HLA-DQB1*02,ADR Directly Studied,The presence of this polymorphism in TNXB may indicate an increased risk of drug-induced ALT-elevations leading to hepatotoxicity when treated with lapatinib.,Details
3,Tenascin-X,---,(C;C) / (C;T),T > C,ADR Directly Studied,The presence of this polymorphism in TNXB may indicate an increased risk of drug-induced ALT-elevations leading to hepatotoxicity when treated with lapatinib.,Details
